Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 167 posts found.

lilly_building_with_american_flag_web

NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer

April 2, 2019
Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology

Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …

News
roche__tree

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019
Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …

News
cancer-cells-541954_960_720

Breast cancer mortality rates fall faster in Britain than elsewhere in Europe

March 19, 2019
Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology

Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …

News

FDA approves first diagnostic tool to target triple-negative breast cancer patients

March 11, 2019
Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma

Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …

News

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …

News

Breast cancer cells can be transformed into fat cells using combination therapy, study shows

January 16, 2019
Research and Development Cancer, EMT, breast cancer, cells, oncology, tumours

An innovative cancer treatment can turn malignant breast cancer cells into fat cells, thus preventing the formation of metastases (the …

News

Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials

December 11, 2018
Manufacturing and Production, Sales and Marketing Cancer, breast cancer, clinical trials, global data, oncology

Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData. The drug, …

News

Galectin-3: The protein paving new treatment avenues

November 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Galectin-3, Galectins, breast cancer, diabetes, heart disease, pharma

Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, …

Feature
lilly_entrance_web

NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance

October 19, 2018
Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma

Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …

News

FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients

October 17, 2018
Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma

Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …

News
roche

Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk

October 16, 2018
Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma

Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …

News

Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer

October 3, 2018
Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …

News

Puma Biotech’s breast cancer drug authorised by European Commission, despite prior concerns

September 5, 2018
Research and Development Cancer, EU, breast cancer, ec approval, puma biotechnology

Puma Biotechnology have received European Commission marketing authorisation for Nerlynx (neratinib) despite prior concerns as to the safety and efficacy …

News
novartis_window

Novartis’ investigational combo impresses in breast cancer sub-group

August 23, 2018
Research and Development Cancer, Novartis, breast cancer, fulvestrant, pharma

Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment …

News

Pfizer notches two EU approvals, including Herceptin biosimilar

August 1, 2018
Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma

Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …

News

Latest content

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023

Acesion Pharma raises €45m series B funding

September 26, 2023

CDC Advisory Committee recommends Pfizer’s RSV vaccine

September 25, 2023

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023